[Skip to Content]
[Skip to Content Landing]
Article
August 1964

Platelet Therapy and Red Cell Defect In Aplastic Anemia

Author Affiliations

BETHESDA, MD

Senior Investigator, Medicine Branch, National Cancer Institute (Dr. Levin); Clinical Associate, Metabolism Service, National Cancer Institute (Dr. Barrett); Clinical Associate, Metabolism Service, National Cancer Institute (present address: Department of Medicine, University of Utah, Salt Lake City) (Dr. Cline); Clinical Director, National Cancer Institute (Dr. Berlin); Senior Investigator, Medicine Branch, National Cancer Institute (Dr. Freireich).; Medicine Branch and Metabolism Service, National Cancer Institute, National Institutes of Health.

Arch Intern Med. 1964;114(2):278-283. doi:10.1001/archinte.1964.03860080128013
Abstract

Transfusions, adrenal corticosteroids, androgens, and splenectomy in the treatment of aplastic anemia have yielded generally unsatisfactory results.1-5 Although hemorrhage due to thrombocytopenia is the most common cause of death in aplastic anemia, platelet transfusions have not been commonly used. The possibility that continued administration of platelets may result in immunization of the recipient and finally refractoriness to transfusion has limited the use of platelet transfusions. However, in studies of repeated transfusions of fresh platelets from the same donor to patients with acute leukemia, only rarely was progressive resistance to platelets noted.6,7

The patient reported here received one to two platelet transfusions weekly for 14 months as prophylaxis and treatment of thrombocytopenia and hemorrhage, and the purpose of this report is to call attention to the efficacy of repeated platelet transfusions in this condition and to studies of the red cell life span during the recovery phase of his

First Page Preview View Large
First page PDF preview
First page PDF preview
×